ArticleRenal failure2025
Respiratory sarcopenia as a mortality predictor for chronic kidney disease: a dual-cohort longitudinal study.
Article in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unravelling Sarcopenia in Chronic Kidney Disease: From Pathogenesis to Diagnosis and Therapeutics.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD) imposes a substantial global health burden. Emerging evidence implicates respiratory sarcopenia as a potential mortality accelerator. This dual-cohort study aimed to clarify the correlation between respiratory sarcopenia and all-cause mortality in CKD populations and evaluate prognostic impacts of longitudinal transitions. We analyzed 1,300 CKD participants without preexisting chronic respiratory conditions from the China Health and Retirement Longitudinal Study (CHARLS) and 1,346 from the U.S. Health and Retirement Study (HRS). Respiratory sarcopenia was defined using surrogate measures, including peak expiratory flow rate for respiratory muscle strength and appendicular skeletal muscle mass index for muscle mass. Multivariable Cox proportional hazards models were employed to assess the associations between respiratory sarcopenia and all-cause mortality. Over median follow-ups of 88 and 96 months, respiratory sarcopenia was associated with a significantly elevated risk of mortality (CHARLS: Hazard Ratio [HR] = 1.61, 95% Confidence Interval [CI] 1.17-2.22; HRS: HR = 1.48, 95% CI 1.07-2.04). Longitudinal progression from non-sarcopenic to respiratory sarcopenic status was associated with an increased risk of mortality (CHARLS: HR = 1.94, 95% CI 1.01-3.76; HRS: HR = 1.82, 95% CI 1.02-3.28), while reversion was associated with a reduced risk of death in the HRS cohort (HR = 0.15, 95% CI 0.03-0.94). Respiratory sarcopenia was independently associated with an increased risk of all-cause mortality in CKD populations using multivariable-adjusted analyses, and reversion from respiratory sarcopenia was associated with a lower risk of mortality. The multi-cohort design strengthens the clinical relevance of these findings, despite limitations from the indirect diagnosis and potential confounding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.